Literature DB >> 34757761

Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.

Massimo Volpe1, Giovanna Gallo1, Speranza Rubattu1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34757761     DOI： 10.1161/HYPERTENSIONAHA.121.18264

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  4 in total

1.  Purification, characterization, and preliminary serial crystallography diffraction advances structure determination of full-length human particulate guanylyl cyclase A receptor.

Authors:  Shangji Zhang; Debra T Hansen; Jose M Martin-Garcia; James D Zook; Shuchong Pan; Felicia M Craciunescu; John C Burnett; Petra Fromme
Journal:  Sci Rep       Date:  2022-07-12       Impact factor: 4.996

2.  MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.

Authors:  Nina A Dzhoyashvili; Seethalakshmi R Iyer; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 10.190

3.  Effects of elevation of ANP and its deficiency on cardiorenal function.

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Kristen Winsor; Gregory R Blass; Denisha R Spires; Elizaveta Sarsenova; Iuliia Polina; Adrian Zietara; Mark Paterson; Alison J Kriegel; Alexander Staruschenko
Journal:  JCI Insight       Date:  2022-05-09

4.  Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension.

Authors:  Valentina Cannone; John C Burnett
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.